Salim Mujais is a Nephrology physician affiliated with Sumitomo Dainippon Pharma. OpenAlex indexes 181 publications with 8,060 citations (h-index 44); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2742 The Mews
Northbrook, IL 600622617
Telephone
847-224-5802Registry record last updated 26 Mar 2014.
Clinical trials
- A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
Sponsor: Prolium Bioscience, Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
2 NIH research awards on record, funded 1987–1989 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
Antimicrobial Agents and Chemotherapy
2017 - QT Interval Shortening With Isavuconazole:<i>In Vitro</i>and<i>In Vivo</i>Effects on Cardiac Repolarization
Clinical Pharmacology & Therapeutics
2017 - Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
European Journal of Clinical Pharmacology
2017 - Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
Antimicrobial Agents and Chemotherapy
2016 - Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study
Clinical Pharmacology & Therapeutics
2012
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”